Tardive Dyskinesia Clinical Trials

54 clinical trials for Tardive Dyskinesia across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia with open-label Part I and randomized, double-blind, placebo-controlled Part II. — RECRUITING · PHASE2
• Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities — RECRUITING · PHASE4
• Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia — RECRUITING · PHASE2
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor — RECRUITING · PHASE4
• An Open label, Safety Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia — RECRUITING · PHASE2
• Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD — RECRUITING · NA
• Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia — RECRUITING · PHASE1
• Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates — RECRUITING · PHASE4
• A Computer-Assisted Tool for Objective Assessment of Extrapyramidal Symptoms — NOT_YET_RECRUITING
• Addressing Involuntary Movements in Tardive Dyskinesia — COMPLETED · PHASE3
• Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia — WITHDRAWN · PHASE2
• Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia — COMPLETED · PHASE4
• Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia — COMPLETED · PHASE2
• Xenazine in Late Dyskinetic Syndrome With Neuroleptics — COMPLETED · PHASE3
• Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine — WITHDRAWN · PHASE1
• ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders — ACTIVE_NOT_RECRUITING · NA
• Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD) — COMPLETED · PHASE2
• Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects — COMPLETED · PHASE1
• Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets — COMPLETED · PHASE1
• Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities — WITHDRAWN · PHASE4
• Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes — OTHER · NA
• A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects — COMPLETED · PHASE1
• Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients — NOT_YET_RECRUITING
• Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia — COMPLETED · NA
• Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia — COMPLETED · NA
• Reducing Involuntary Movements in Participants With Tardive Dyskinesia — COMPLETED · PHASE3
• Aim to Reduce Movements in Tardive Dyskinesia — COMPLETED · PHASE2
• Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia — COMPLETED · PHASE4
• Pimavanserin Treatment in TS — COMPLETED · PHASE1
• The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine — COMPLETED · PHASE4
• Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia — WITHDRAWN · PHASE2
• Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia — TERMINATED · PHASE2
• Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia — COMPLETED · PHASE3
• Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia — COMPLETED · PHASE3
• D-Serine Treatment For Tardive Dyskinesia — OTHER · NA
• Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia. — OTHER · NA
• Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents — OTHER
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) — COMPLETED · PHASE2
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder — COMPLETED · PHASE2
• NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia — COMPLETED · PHASE2
• A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia — COMPLETED · PHASE3
• Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia — TERMINATED · NA
• The Assessment of Movement Disorders Utilizing Live Two-Way Video — COMPLETED
• Melatonin Treatment for Tardive Dyskinesia in Schizophrenia — COMPLETED · NA
• A PHASE 3, OPEN-LABEL, SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF TARDIVE DYSKINESIA — COMPLETED · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, FIXED-DOSE STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF NBI-98854 FOR THE TREATMENT OF TARDIVE DYSKINESIA — COMPLETED · PHASE3
• Levetiracetam Treatment of Tardive Dyskinesia — COMPLETED · PHASE3
• Pyridoxal Kinase Activity in Tardive Dyskinesia — WITHDRAWN · PHASE3
• Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia — COMPLETED · PHASE1
• Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia — COMPLETED · PHASE2

Refine this search